|Phenotypic and molecular characterization of the claudin-low intrinsic subtype of breast cancer|
A Prat, JS Parker, O Karginova, C Fan, C Livasy, JI Herschkowitz, X He, ...
Breast cancer research 12 (5), 1-18, 2010
|Identification of conserved gene expression features between murine mammary carcinoma models and human breast tumors|
JI Herschkowitz, K Simin, VJ Weigman, I Mikaelian, J Usary, Z Hu, ...
Genome biology 8 (5), 1-17, 2007
|Residual breast cancers after conventional therapy display mesenchymal as well as tumor-initiating features|
CJ Creighton, X Li, M Landis, JM Dixon, VM Neumeister, A Sjolund, ...
Proceedings of the National Academy of Sciences 106 (33), 13820-13825, 2009
|Core epithelial-to-mesenchymal transition interactome gene-expression signature is associated with claudin-low and metaplastic breast cancer subtypes|
JH Taube, JI Herschkowitz, K Komurov, AY Zhou, S Gupta, J Yang, ...
Proceedings of the National Academy of Sciences 107 (35), 15449-15454, 2010
|The pINDUCER lentiviral toolkit for inducible RNA interference in vitro and in vivo|
KL Meerbrey, G Hu, JD Kessler, K Roarty, MZ Li, JE Fang, JI Herschkowitz, ...
Proceedings of the National Academy of Sciences 108 (9), 3665-3670, 2011
|The functional loss of the retinoblastoma tumour suppressor is a common event in basal-like and luminal B breast carcinomas|
JI Herschkowitz, X He, C Fan, CM Perou
Breast Cancer Research 10 (5), 1-13, 2008
|FOXC2 expression links epithelial–mesenchymal transition and stem cell properties in breast cancer|
BG Hollier, AA Tinnirello, SJ Werden, KW Evans, JH Taube, TR Sarkar, ...
Cancer research 73 (6), 1981-1992, 2013
|Comparative oncogenomics identifies breast tumors enriched in functional tumor-initiating cells|
JI Herschkowitz, W Zhao, M Zhang, J Usary, G Murrow, D Edwards, ...
Proceedings of the National Academy of Sciences 109 (8), 2778-2783, 2012
|Characterization of mammary tumors from Brg1 heterozygous mice|
SJ Bultman, JI Herschkowitz, V Godfrey, TC Gebuhr, M Yaniv, CM Perou, ...
Oncogene 27 (4), 460-468, 2008
|Gene expression patterns associated with p53 status in breast cancer|
MA Troester, JI Herschkowitz, DS Oh, X He, KA Hoadley, CS Barbier, ...
BMC cancer 6 (1), 1-13, 2006
|Transcriptomic classification of genetically engineered mouse models of breast cancer identifies human subtype counterparts|
AD Pfefferle, JI Herschkowitz, J Usary, JC Harrell, BT Spike, JR Adams, ...
Genome biology 14 (11), 1-16, 2013
|Rb deletion in mouse mammary progenitors induces luminal-B or basal-like/EMT tumor subtypes depending on p53 status|
Z Jiang, T Deng, R Jones, H Li, JI Herschkowitz, JC Liu, VJ Weigman, ...
The Journal of clinical investigation 120 (9), 3296-3309, 2010
|ETV6-NTRK3 fusion oncogene initiates breast cancer from committed mammary progenitors via activation of AP1 complex|
Z Li, CE Tognon, FJ Godinho, L Yasaitis, H Hock, JI Herschkowitz, ...
Cancer cell 12 (6), 542-558, 2007
|Epigenetic silencing of microRNA-203 is required for EMT and cancer stem cell properties|
JH Taube, GG Malouf, E Lu, N Sphyris, V Vijay, PP Ramachandran, ...
Scientific reports 3 (1), 1-10, 2013
|RB1 and p53 at the crossroad of EMT and triple-negative breast cancer|
Z Jiang, R Jones, JC Liu, T Deng, T Robinson, PED Chung, S Wang, ...
Cell cycle 10 (10), 1563-1570, 2011
|Oncogenic mTOR signalling recruits myeloid-derived suppressor cells to promote tumour initiation|
T Welte, IS Kim, L Tian, X Gao, H Wang, J Li, XB Holdman, ...
Nature cell biology 18 (6), 632-644, 2016
|c-Myc and Her2 cooperate to drive a stem-like phenotype with poor prognosis in breast cancer|
R Nair, DL Roden, WS Teo, A McFarland, S Junankar, S Ye, A Nguyen, ...
Oncogene 33 (30), 3992-4002, 2014
|The ups and downs of miR-205: identifying the roles of miR-205 in mammary gland development and breast cancer|
SB Greene, JI Herschkowitz, JM Rosen
RNA biology 7 (3), 300-304, 2010
|Met synergizes with p53 loss to induce mammary tumors that possess features of claudin-low breast cancer|
JF Knight, R Lesurf, H Zhao, D Pinnaduwage, RR Davis, SMI Saleh, ...
Proceedings of the National Academy of Sciences 110 (14), E1301-E1310, 2013
|Predicting drug responsiveness in human cancers using genetically engineered mice|
J Usary, W Zhao, D Darr, PJ Roberts, M Liu, L Balletta, O Karginova, ...
Clinical Cancer Research 19 (17), 4889-4899, 2013